Invested $200K in Saku Biosciences, a fermentation-enhancement platform using directed evolution, through GFIF II Cohort 4.
MAY 18, 2026
Saku Biosciences is an early-stage life sciences company improving the economics of biomanufacturing
Saku Biosciences is an early-stage life sciences company improving the economics of biomanufacturing. We deliver high-performance host cell products that increase titers, strengthen supply chains through alternative feedstocks, and reduce downstream processing costs. Using PicoShell screening technology, Saku compresses host-cell engineering timelines from years to months, enabling faster iteration of industry-ready, high-performing host cells.